RxDoctor Payments Data

Larry Kramer, DO

Family Medicine · Phila, PANPI 1407830086

Payments from drug & device makers

$1,808in general payments, 2019–2025

Across 78 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$292
  • Amarin Pharma, Inc.$280
  • Daiichi Sankyo Inc.$213
  • AbbVie$166
  • Novartis$151
  • GSK$102
  • plus $603 from 15 others

What the payments were for

  • Food & beverage$1,802100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,808 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$101,631
Medicare patients
212
Services billed
1,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate127$124,939
TrulicityDulaglutide80$91,175
EliquisApixaban110$75,837
JardianceEmpagliflozin41$32,858
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$32,243
XareltoRivaroxaban36$22,215
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr40$20,687
LinzessLinaclotide33$19,913
JanumetSitagliptin Phos/Metformin Hcl22$19,368
TradjentaLinagliptin20$13,911
VascepaIcosapent Ethyl28$13,073
Diclofenac Sodium266$12,893
EntrestoSacubitril/Valsartan19$12,561
MounjaroTirzepatide11$11,452
Humulin R U-500 KwikpenInsulin Regular, Human19$10,613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$67$144,308149 claims
PfizerEliquis$292$75,837110 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$102$59,307107 claims
Boehringer IngelheimJardiance, Tradjenta$30$46,76961 claims
Johnson & JohnsonXarelto$65$22,21536 claims
AstraZenecaBrilinta, Pulmicort Flexhaler, Symbicort$12$19,95047 claims
AbbVieLinzess$166$19,91333 claims
NovartisEntresto$151$12,56119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Phila

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →